The number and size of the tumor, like in the Milan criteria or Metroticket, are clearly insufficient for prognostication and only the addition of angiopoietin-2 for Milan criteria, or AFP for Metroticket, makes them able to discriminate between low and high risk of the event. The gene discussed is AFP; the disease is neoplasm.